OVARIAN CANCER and US: Fenretinide

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label Fenretinide. Show all posts
Showing posts with label Fenretinide. Show all posts

Tuesday, February 21, 2012

Phase 1/11 Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer - Full Text View - ClinicalTrials.gov



 Wiki:  
Fenretinide (4-hydroxy(phenyl)retinamide; 4-HPR) (INN) is a synthetic retinoid deriverative. Retinoids are substances related to vitamin A.

 Wiki:
Ketoconazole (play /ˌktɵˈknəzɒl/) is a synthetic antifungal drug used to prevent and treat fungal skin infections, especially in immunocompromised patients such as those with AIDS or those on chemotherapy. 

~~~~~~~~~~~~~~~~~~~~
  
Criteria

Inclusion Criteria:
  • Recurrent epithelial ovarian cancer or primary peritoneal carcinoma that can be platinum sensitive or platinum resistant
  • SWOG Performance Status 0-2
  • Previously received a platinum and paclitaxel containing regimen
  • Projected Life Expectancy of at least 3 months
  • Adequate bone marrow function
  • Adequate organ function
  • Must have received at least 1 prior salvage regimen for recurrent ovarian cancer
  • Recovery from acute toxicities from surgery, radiation or chemotherapy
  • At least 3 weeks from last therapy
Exclusion Criteria:
  • Prior fenretinide oral capsule use allowed. If prior IV fenretinide use, must contact study chair for eligibility
  • Second malignancy within last 5 years
  • Use of concomitant antioxidants, such as vitamin C or E
  • Untreated or symptomatic brain metastases
  • History of hypertriglyceride levels > 200 mg/dl; triglyceride levels < 200 and receiving treatment are okay.
  • Use of certain medications is prohibited - contact study coordinator for information